These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 15239140)

  • 1. Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis.
    Sheng Y; Hua J; Pinney KG; Garner CM; Kane RR; Prezioso JA; Chaplin DJ; Edvardsen K
    Int J Cancer; 2004 Sep; 111(4):604-10. PubMed ID: 15239140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate.
    Hua J; Sheng Y; Pinney KG; Garner CM; Kane RR; Prezioso JA; Pettit GR; Chaplin DJ; Edvardsen K
    Anticancer Res; 2003; 23(2B):1433-40. PubMed ID: 12820406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations in vascular architecture and permeability following OXi4503 treatment.
    Chan LS; Malcontenti-Wilson C; Muralidharan V; Christophi C
    Anticancer Drugs; 2008 Jan; 19(1):17-22. PubMed ID: 18043126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular targeting agent Oxi4503 inhibits tumor growth in a colorectal liver metastases model.
    Malcontenti-Wilson C; Chan L; Nikfarjam M; Muralidharan V; Christophi C
    J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e96-e104. PubMed ID: 17559382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of vascular targeting agent Oxi4503 on tumor cell kinetics in a mouse model of colorectal liver metastasis.
    Chan LS; Malcontenti-Wilson C; Muralidharan V; Christophi C
    Anticancer Res; 2007; 27(4B):2317-23. PubMed ID: 17695520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503.
    Rice L; Pampo C; Lepler S; Rojiani AM; Siemann DW
    Microvasc Res; 2011 Jan; 81(1):44-51. PubMed ID: 20974154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spatial morphological and molecular differences within solid tumors may contribute to the failure of vascular disruptive agent treatments.
    Nguyen L; Fifis T; Malcontenti-Wilson C; Chan LS; Costa PN; Nikfarjam M; Muralidharan V; Christophi C
    BMC Cancer; 2012 Nov; 12():522. PubMed ID: 23153292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity.
    Salmon HW; Siemann DW
    Clin Cancer Res; 2006 Jul; 12(13):4090-4. PubMed ID: 16818709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combretastatin A-4 prodrug: a potent inhibitor of malignant hemangioendothelioma cell proliferation.
    Böhle AS; Leuschner I; Kalthoff H; Henne-Bruns D
    Int J Cancer; 2000 Sep; 87(6):838-43. PubMed ID: 10956395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The new vascular disrupting agent combretastatin-A1-disodium-phosphate (OXi4503) enhances tumour response to mild hyperthermia and thermoradiosensitization.
    Hokland SL; Horsman MR
    Int J Hyperthermia; 2007 Nov; 23(7):599-606. PubMed ID: 18038290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability.
    Tozer GM; Prise VE; Wilson J; Cemazar M; Shan S; Dewhirst MW; Barber PR; Vojnovic B; Chaplin DJ
    Cancer Res; 2001 Sep; 61(17):6413-22. PubMed ID: 11522635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4.
    Iyer S; Chaplin DJ; Rosenthal DS; Boulares AH; Li LY; Smulson ME
    Cancer Res; 1998 Oct; 58(20):4510-4. PubMed ID: 9788591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
    Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM
    Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective role of vascular endothelial growth factor in endotoxin-induced acute lung injury in mice.
    Koh H; Tasaka S; Hasegawa N; Yamada W; Shimizu M; Nakamura M; Yonemaru M; Ikeda E; Adachi Y; Fujishima S; Yamaguchi K; Ishizaka A
    Respir Res; 2007 Aug; 8(1):60. PubMed ID: 17718922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate.
    Chaplin DJ; Pettit GR; Hill SA
    Anticancer Res; 1999; 19(1A):189-95. PubMed ID: 10226542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of fibroblast growth factor-2-induced vascular tumor formation by the acyclic nucleoside phosphonate cidofovir.
    Liekens S; Neyts J; De Clercq E; Verbeken E; Ribatti D; Presta M
    Cancer Res; 2001 Jul; 61(13):5057-64. PubMed ID: 11431341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors.
    Patterson DM; Zweifel M; Middleton MR; Price PM; Folkes LK; Stratford MR; Ross P; Halford S; Peters J; Balkissoon J; Chaplin DJ; Padhani AR; Rustin GJ
    Clin Cancer Res; 2012 Mar; 18(5):1415-25. PubMed ID: 22235096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased secretion of vascular endothelial growth factor is associated with increased apoptosis in vascular tumor derived endothelial cells.
    Mabeta P
    J Physiol Pharmacol; 2013 Aug; 64(4):473-7. PubMed ID: 24101393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The vascular endothelial growth factor (VEGF)/VEGF receptor 2 pathway is critical for blood vessel survival in corpora lutea of pregnancy in the rodent.
    Pauli SA; Tang H; Wang J; Bohlen P; Posser R; Hartman T; Sauer MV; Kitajewski J; Zimmermann RC
    Endocrinology; 2005 Mar; 146(3):1301-11. PubMed ID: 15591152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin.
    Goto H; Yano S; Matsumori Y; Ogawa H; Blakey DC; Sone S
    Clin Cancer Res; 2004 Nov; 10(22):7671-6. PubMed ID: 15570000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.